PD-L1 Inhibitor as a drug in cancer therapeutics

How to Cite

Xuxiong. (2019). PD-L1 Inhibitor as a drug in cancer therapeutics. American Journal of Translational Medicine, 3(4), 127–139. Retrieved from https://ajtm.journals.publicknowledgeproject.org/index.php/ajtm/article/view/637


PD-1 signaling negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to evade an antigen-specific T cell immunologic response. It plays a role in promoting cancer development and progression by enhancing tumor cell survival. With this background, PD-1 signaling represents a valuable therapeutic target for novel and effective cancer immunotherapy. Clinical data shows that blockade of this PD-1 signaling significantly enhance antitumor immunity, produce durable clinical responses, and prolong survival. Currently, there are three FDA-approved PD-L1 inhibitors for various malignancies ranging from non-small cell lung cancer to Merkel cell carcinoma. The aim of this review is to summarize many ongoing phase II/III trials of Atezolizumab, Durvalumab, Avelumab, and new PD-L1 inhibitors in clinical developments. We focus on key trials that paved the pathway to FDA-approved indications for Atezolizumab, Durvalumab, and Avelumab. Further considerations in mechanisms of resistance, treatment duration, immune-related toxicities, and PD-L1 expression threshold are needed to optimize anticancer potential in this class of immunotherapy (Am J Transl Med 2019. 3:127-139).